Mark Dolev

2.1k total citations · 1 hit paper
50 papers, 1.4k citations indexed

About

Mark Dolev is a scholar working on Pathology and Forensic Medicine, Neurology and Infectious Diseases. According to data from OpenAlex, Mark Dolev has authored 50 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pathology and Forensic Medicine, 14 papers in Neurology and 9 papers in Infectious Diseases. Recurrent topics in Mark Dolev's work include Multiple Sclerosis Research Studies (40 papers), Peripheral Neuropathies and Disorders (12 papers) and SARS-CoV-2 and COVID-19 Research (9 papers). Mark Dolev is often cited by papers focused on Multiple Sclerosis Research Studies (40 papers), Peripheral Neuropathies and Disorders (12 papers) and SARS-CoV-2 and COVID-19 Research (9 papers). Mark Dolev collaborates with scholars based in Israel, Switzerland and Slovakia. Mark Dolev's co-authors include Anat Achiron, David Magalashvili, Shay Menascu, Michael Gurevich, Yael Stern, Uri Givon, Alon Kalron, Sapir Dreyer-Alster, Shlomo Flechter and Gil Harari and has published in prestigious journals such as PLoS ONE, Neurology and Scientific Reports.

In The Last Decade

Mark Dolev

50 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

2021 235 citations Anat Achiron, Mathilda Mandel et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Dolev Israel	18	1.0k	441	441	257	141	50	1.4k
David Magalashvili Israel	16	810 0.8×	385 0.9×	441 1.0×	222 0.9×	150 1.1×	48	1.1k
Abdorreza Naser Moghadasi Iran	21	1.1k 1.1×	628 1.4×	243 0.6×	218 0.8×	135 1.0×	224	1.8k
Robert Hoepner Switzerland	19	543 0.5×	324 0.7×	169 0.4×	169 0.7×	292 2.1×	96	1.1k
Katharina Fink Sweden	20	1.1k 1.0×	475 1.1×	201 0.5×	488 1.9×	482 3.4×	65	2.1k
Romain Deschamps France	19	795 0.8×	651 1.5×	274 0.6×	110 0.4×	153 1.1×	76	1.3k
Vahid Shaygannejad Iran	17	672 0.7×	339 0.8×	103 0.2×	111 0.4×	76 0.5×	74	945
Edgardo Cristiano Argentina	23	1.1k 1.1×	486 1.1×	75 0.2×	211 0.8×	147 1.0×	116	1.7k
Amir‐Hadi Maghzi United States	19	569 0.6×	291 0.7×	115 0.3×	131 0.5×	65 0.5×	44	960
Shlomo Flechter Israel	15	606 0.6×	320 0.7×	433 1.0×	294 1.1×	105 0.7×	39	1.0k
Yael Stern Israel	11	526 0.5×	258 0.6×	170 0.4×	132 0.5×	57 0.4×	15	679

Countries citing papers authored by Mark Dolev

Since Specialization

Citations

This map shows the geographic impact of Mark Dolev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Dolev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Dolev more than expected).

Fields of papers citing papers by Mark Dolev

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Dolev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Dolev. The network helps show where Mark Dolev may publish in the future.

Co-authorship network of co-authors of Mark Dolev

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Dolev. A scholar is included among the top collaborators of Mark Dolev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Dolev. Mark Dolev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gurevich, Michael, Rina Zilkha‐Falb, J L Sherman, et al.. (2024). Machine learning–based prediction of disease progression in primary progressive multiple sclerosis. Brain Communications. 7(1). fcae427–fcae427. 1 indexed citations

Menascu, Shay, Sapir Dreyer-Alster, David Magalashvili, et al.. (2023). Intravenous immunoglobulin treatment during pregnancy and the post-partum period in women with multiple sclerosis: A prospective analysis. Multiple Sclerosis Journal - Experimental Translational and Clinical. 9(1). 3090514327–3090514327. 4 indexed citations

Harari, Gil, Michael Gurevich, Mark Dolev, Rina Falb, & Anat Achiron. (2023). Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study. PLoS ONE. 18(2). e0280515–e0280515. 4 indexed citations

Magalashvili, David, Sapir Dreyer-Alster, Chen Hoffmann, et al.. (2023). Radiological Disease Activity in Secondary Progressive Multiple Sclerosis. European Neurology. 86(2). 116–120. 2 indexed citations

Dreyer-Alster, Sapir, Shay Menascu, Mark Dolev, et al.. (2022). Longitudinal relationships between disability and gait characteristics in people with MS. Scientific Reports. 12(1). 3653–3653. 6 indexed citations

Dreyer-Alster, Sapir, Shay Menascu, Mathilda Mandel, et al.. (2022). COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose. Journal of the Neurological Sciences. 434. 120155–120155. 40 indexed citations

Menascu, Shay, Roy Aloni, Mark Dolev, et al.. (2021). Targeted cognitive game training enhances cognitive performance in multiple sclerosis patients treated with interferon beta 1-a. Journal of NeuroEngineering and Rehabilitation. 18(1). 175–175. 6 indexed citations

Achiron, Anat, Mathilda Mandel, Sapir Dreyer-Alster, et al.. (2021). Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study. Journal of Neuroimmunology. 361. 577746–577746. 56 indexed citations

Gurevich, Michael, Rina Zilkha‐Falb, Polina Sonis, et al.. (2021). SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients. International Journal of Infectious Diseases. 115. 208–214. 17 indexed citations

10.

Achiron, Anat, Sapir Dreyer-Alster, Michael Gurevich, et al.. (2021). Definitions of primary-progressive multiple sclerosis trajectories by rate of clinical disability progression. Multiple Sclerosis and Related Disorders. 50. 102814–102814. 3 indexed citations

11.

Menascu, Shay, Aviva Fattal‐Valevski, Adi Vaknin‐Dembinsky, et al.. (2021). Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage. Journal of the Neurological Sciences. 432. 120074–120074. 6 indexed citations

12.

Dolev, Mark, et al.. (2021). The association between bladder dysfunction, balance and falls in women with multiple sclerosis: The specific contribution of fear of falling. Gait & Posture. 88. 252–257. 3 indexed citations

13.

Achiron, Anat, Alon Ben‐David, Michael Gurevich, et al.. (2020). Parity and disability progression in relapsing–remitting multiple sclerosis. Journal of Neurology. 267(12). 3753–3762. 12 indexed citations

14.

Kalron, Alon, Roy Aloni, Mark Dolev, et al.. (2018). The relationship between gait variability and cognitive functions differs between fallers and non-fallers in MS. Journal of Neural Transmission. 125(6). 945–952. 14 indexed citations

15.

Kalron, Alon, David Magalashvili, Mark Dolev, et al.. (2015). A personalized, intense physical rehabilitation program improves walking in people with multiple sclerosis presenting with different levels of disability: a retrospective cohort. BMC Neurology. 15(1). 21–21. 27 indexed citations

16.

Achiron, Anat, Joab Chapman, David Magalashvili, et al.. (2013). Modeling of Cognitive Impairment by Disease Duration in Multiple Sclerosis: A Cross-Sectional Study. PLoS ONE. 8(8). e71058–e71058. 119 indexed citations

17.

Achiron, Anat, et al.. (2004). Understanding Autoimmune Mechanisms in Multiple Sclerosis Using Gene Expression Microarrays: Treatment Effect and Cytokine‐related Pathways. Journal of Immunology Research. 11(3-4). 299–305. 22 indexed citations

18.

Achiron, Anat, I Sarova-Pinhàs, Meir Faibel, et al.. (2004). Intravenous Immunoglobulin Treatment Following the First Demyelinating Event Suggestive of Multiple Sclerosis. Archives of Neurology. 61(10). 1515–1515. 74 indexed citations

19.

Zeilig, Gabi, et al.. (2000). Long-term morbidity and mortality after spinal cord injury: 50 years of follow-up. Spinal Cord. 38(9). 563–566. 27 indexed citations

20.

Talmi, Yoav P., Nachshon Knoller, Mark Dolev, et al.. (2000). Postsurgical Prevertebral Abscess of the Cervical Spine. The Laryngoscope. 110(7). 1137–1141. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact